BTS
MYGN icon

BB&T Securities’s Myriad Genetics MYGN Stock Holding History

BB&T Securities’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-5,543
Closed -$254K – 1563
2018
Q3 		$254K Buy
+5,543
New +$246K ﹤0.01% 1389
2018
Q1 		– Sell
-5,990
Closed -$205K – 1540
2017
Q4 		$205K Sell
5,990
-5,348
-47% -$180K ﹤0.01% 1340
2017
Q3 		$410K Sell
11,338
-188,765
-94% -$5.38M 0.01% 1041
2017
Q2 		$5.17M Sell
200,103
-705,107
-78% -$15M 0.08% 321
2017
Q1 		$17.4M Buy
905,210
+7,754
+0.9% +$137K 0.24% 106
2016
Q4 		$18.5M Hold
897,456
– – 0.27% 101
2016
Q3 		$18.5M Buy
897,456
+238,285
+36% +$6.04M 0.28% 98
2016
Q2 		$20.2M Buy
659,171
+25,478
+4% +$885K 0.31% 88
2016
Q1 		$23.7M Buy
633,693
+2,148
+0.3% +$80.9K 0.39% 68
2015
Q4 		$27.3M Sell
631,545
-99,901
-14% -$4.22M 0.57% 57
2015
Q3 		$27.4M Buy
731,446
+13,795
+2% +$490K 0.6% 51
2015
Q2 		$24.4M Buy
717,651
+113,130
+19% +$3.85M 0.52% 57
2015
Q1 		$21.4M Buy
604,521
+10,515
+2% +$376K 0.47% 59
2014
Q4 		$20.2M Buy
594,006
+7,460
+1% +$265K 0.46% 58
2014
Q3 		$22.6M Buy
586,546
+3,046
+0.5% +$114K 0.53% 55
2014
Q2 		$22.7M Sell
583,500
-131,537
-18% -$4.89M 0.54% 53
2014
Q1 		$24.4M Sell
715,037
-171,276
-19% -$5.31M 0.63% 49
2013
Q4 		$18.6M Buy
886,313
+63,120
+8% +$1.6M 0.51% 53
2013
Q3 		$19.3M Buy
823,193
+82,768
+11% +$2.35M 0.6% 52
2013
Q2 		$19.9M Buy
+740,425
New +$21.5M 0.65% 49

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

BB&T Securities's MYGN Position: Q4 2018 in Review

BB&T Securities sold out of Myriad Genetics (MYGN) in Q4 2018, closing a stake of 5,543 shares — an estimated $254K sold.

BB&T Securities first reported a position in MYGN in Q2 2013 and held it in 20 quarters. The position peaked at $27.4M in Q3 2015. 264 funds tracked by Wall St. Rank hold MYGN as of Q4 2018.

  • BB&T Securities reported no remaining Myriad Genetics position as of Q4 2018 after selling out during the quarter.
  • BB&T Securities sold 5,543 Myriad Genetics shares in Q4 2018, an estimated $254K.
  • BB&T Securities first reported a position in Myriad Genetics in Q2 2013 and held it in 20 quarters.
  • BB&T Securities's Myriad Genetics position peaked at $27.4M in Q3 2015.
  • 264 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2018.

Based on BB&T Securities's 13F filing for Q4 2018, filed 4 Feb 2019.